Search Results
Your search for The ASCO Post ,The ASCO Post matches 16993 pages
Showing 4551 - 4600
Rebecca S. Kristeleit, MD, PhD, on Relapsed Ovarian Cancer: Rucaparib vs Chemotherapy
Rebecca S. Kristeleit, MD, PhD, of the University College London and UCL Cancer Institute, discusses efficacy and safety results from the phase III ARIEL4 study, which showed that rucaparib improved progression-free survival vs standard-of-care chemotherapy in patients with BRCA-mutated,...
Arlene O. Siefker-Radtke, MD, on Urothelial Bladder Cancer: New Settings for Immune Checkpoint Inhibitors
Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses the changing therapeutic landscape in which atezolizumab, avelumab, and pembrolizumab have either been approved or are under review for treating urothelial bladder cancer in the metastatic, superficial,...
Vicky Makker, MD, on Endometrial Cancer: Lenvatinib Plus Pembrolizumab
Vicky Makker, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings showing that lenvatinib plus pembrolizumab may improve overall and progression-free survival, as well as overall response rate, compared with treatment of physician’s choice for advanced endometrial cancer....
Robert Winn, MD, on Strategies for Reducing Racial Disparities in Oncology
Robert Winn, MD, of the Virginia Commonwealth University Massey Cancer Center, discusses the creation of a health equity report card to track how institutions are dealing with disparities in oncology care, ways to recognize bias in care, and adding health equity experts to guideline panels and...
William J. Gradishar, MD, on Triple-Negative Breast Cancer: NCCN Guidelines Update
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the latest recommendations from the National Comprehensive Cancer Network for treating patients with triple-negative breast cancer; data on early-stage and advanced disease; and the role...
DCIS Biologic Risk Signature May Predict Risk of Recurrence and Radiation Benefit After Breast-Conserving Surgery
Women with ductal carcinoma in situ (DCIS) and elevated decision scores had a significantly higher risk of ipsilateral breast events and a greater relative benefit from radiation therapy compared to women with lower decision scores, according to research presented by Mann et al at the Society of...
Predicting Survival in Patients With Extremity and Trunk Sarcomas in the United States
An examination of the online nomogram Sarculator demonstrated it is as effective at predicting overall survival of certain patients with sarcoma in the United States as it is in Europe, according to research presented by Voss et al at the Society of Surgical Oncology 2021 International Conference...
Utilization and Survival Benefit of Adjuvant Immunotherapy for Resected High-Risk Stage II Melanoma
An observational study of 10,592 patients from the National Cancer Database with stage IIB/IIC melanoma who had undergone surgical resection demonstrated a significant survival advantage with immunotherapy. The research was presented by Wong et al at the Society of Surgical Oncology 2021...
Shivan J. Mehta, MD, MBA, on Preventing and Controlling HPV-Associated Cancers
Shivan J. Mehta, MD, MBA, of Abramson Cancer Center at the University of Pennsylvania, discusses how insights from behavioral economics could be harnessed to improve HPV vaccination rates, thus lowering the rate of cervical, genital, and head/neck cancers, all of which are linked to HPV.
Sandy Srinivas, MD, on Managing Metastatic Castration-Resistant Prostate Cancer
Sandy Srinivas, MD, of Stanford Cancer Institute, discusses the increasing number of ways to deliver life-prolonging therapy to patients with advanced prostate cancer, including more accurate imaging techniques; PET tracers to help better detect, diagnose, and treat disease; PARP inhibitors for...
FDA Approves TheraSphere Y-90 Glass Microspheres for Unresectable Hepatocellular Carcinoma
Today, the U.S. Food and Drug Administration (FDA) approved TheraSphere Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma. The approval expands access to this therapy, which, to date, has been utilized under a humanitarian device exemption—an FDA...
Improving the Prognostic Accuracy of Residual Cancer Burden After Neoadjuvant Chemotherapy for Breast Cancer
An analysis of 546 patients with breast cancer who received neoadjuvant chemotherapy demonstrated that residual cancer burden is prognostic for overall survival, recurrence-free survival, and distant relapse–free survival, according to research presented by White et al at the Society of Surgical...
Circulating Hybrid Cells May Help to Monitor Treatment Response in Patients With Rectal and Esophageal Cancers
An analysis of 58 peripheral blood specimens from patients with rectal and esophageal cancers demonstrated that circulating hybrid cells may be a novel, noninvasive biomarker with potential for monitoring treatment response and disease progression to help guide decisions for further therapy,...
FDA Pipeline: Priority Review for Kidney Cancer Treatment, Fast Track Designation for NSCLC Treatment
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to the HIF-2α inhibitor belzutifan for the treatment of patients with von Hippel-Lindau (VHL) disease–associated renal cell carcinoma. The agency also granted Fast Track designation to poziotinib for the treatment of...
Using CT Colonography as a Noninvasive Colorectal Cancer Screening Test for Advanced Neoplasia
According to a report published by Pickhardt et al in the American Journal of Roentgenology (AJR), compared with multitarget stool DNA and fecal immunochemical tests, computed tomography (CT) colonography using a polyp size threshold ≥ 10 mm most effectively targeted advanced neoplasia—preserving...
Can Treatment for Prostate Cancer Affect Smell and Taste?
One in six men being treated for advanced prostate cancer reported experiencing a reduced sense of smell and taste, according to a study published by Alonzi et al in the journal Supportive Care in Cancer. The study authors noted that a reduced sense of smell and taste among some patients with...
High Tumor Mutational Burden Predicts Immunotherapy Response in Some—but Not All—Cancers
High tumor mutational burden (TMB) was useful for predicting clinical responses to immune checkpoint inhibitors only in a subset of cancer types, according to a study published by McGrail et al in Annals of Oncology. The findings suggest that TMB status may not be reliably used as a universal...
Study Identifies Factors That May Lower the Risk of CNS Relapse in Pediatric Patients With ALL
Starting chemotherapy several days before the first lumbar puncture for diagnosis and treatment of acute lymphoblastic leukemia (ALL) may reduce the risk of central nervous system (CNS) relapse in children, according to a study published by Tang et al in the journal Blood. The research focused on...
Is HPV Vaccination for Adults Aged 26 and Older Cost-Effective?
Vaccinating adults aged 26 and older against the human papillomavirus (HPV) may not be cost-effective, according to a new study published by Kim et al in PLOS Medicine. “Our study found that the added health benefit of increasing the vaccination age limit beyond 26 years is minimal, and that the...
Lowering KRAS Activity May Lead to Improved Therapy Response in Pancreatic Cancer
If clinicians could stop mutations of the KRAS gene—which are present in more than 90% of pancreatic cancer cases and drastically reduce the response to immunotherapy—the chances of improving treatment for the disease would be increased. A collaborative study published by Ischenko et al in Nature...
Study Finds Regularly Drinking Sugar-Sweetened Soda May Increase Total and Breast Cancer Mortality
New research published by Koyratty et al in Cancer Epidemiology, Biomarkers & Prevention suggests that patients with breast cancer who drink sugar-sweetened beverages regularly are at increased risk for death from any cause, and from breast cancer in particular. Compared to women who never or...
FDA Oncologic Drugs Advisory Committee to Review Status of Six Indications Granted Accelerated Approval
Recently, the U.S. Food and Drug Administration (FDA) announced that the agency will hold a public meeting of the Oncologic Drugs Advisory Committee on April 27 to 29 to discuss six indications granted accelerated approval that have since reported results from confirmatory trials that have not...
Expect Questions From Older Breast Cancer Survivors About Discontinuing Routine Surveillance Mammography
Consensus guidelines recommending that routine surveillance mammography be discontinued for older breast cancer survivors with a limited life expectancy1 may raise questions among patients concerned about undetected cancer recurrence. Informing older survivors about the new recommendations and the...
Older Breast Cancer Survivors May Consider Discontinuing Screening Mammography in the Setting of Limited Life Expectancy
Newly issued mammography screening guidelines for breast cancer survivors aged 75 and older recommend discontinuing routine mammography for those with a life expectancy of less than 5 years and considering discontinuation of routine screening for those with a life expectancy between 5 and 10 years. ...
New Survey Reveals Hesitancy Around COVID-19 Vaccination Among Patients With Hematologic Malignancies and Survivors
A survey of more than 6,500 U.S. patients with blood cancer and survivors revealed that only half are very likely to get a COVID-19 vaccine, while one in three is either unlikely or unsure about it. The nationwide survey was a collaboration between The Leukemia & Lymphoma Society (LLS), Boston...
Why Might Night-Shift Workers Have a Higher Risk of Developing Cancer?
New clues as to why night-shift workers are at an increased risk of developing certain types of cancer were uncovered in a new study published by Koritala et al in the Journal of Pineal Research. The study involved a controlled laboratory experiment that used healthy volunteers who were on...
Miami Breast Cancer Conference: Genomic Assays Show Utility in Predicting Pathologic Complete Response Rate in Pre- and Postmenopausal Patients With Breast Cancer
New data from the prospective Neoadjuvant Breast Symphony Trial (NBRST), which demonstrated the predictive and prognostic abilities of the MammaPrint and BluePrint assays and underpinned their preoperative utility in pre-and postmenopausal patients with breast cancer, were presented at PER’s Miami...
New Study Finds Muscle Mass and Density Are Correlated With Survival and Outcomes in Patients With Advanced Cancer
New research published by van Seventer et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that muscle mass was correlated with survival, while muscle radiodensity was associated with symptom burden, health-care use, and survival in patients with advanced cancer undergoing ...
FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma
On March 10, the U.S. Food and Drug Administration (FDA) approved tivozanib (Fotivda), a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies. TIVO-3 Efficacy was evaluated in TIVO-3 (ClinicalTrials.gov...
ASCO and Friends of Cancer Research Recommend Expanding Patient Access to Cancer Clinical Trials by Further Broadening Eligibility Criteria
ASCO and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients.1 The joint recommendations are detailed in a series of articles...
Yale School of Medicine Announces New Section Chief of Breast Surgery
Rachel Adams Greenup, MD, MPH, FACS, has been appointed Associate Professor of Surgery (Oncology) and Section Chief of Breast Surgery for the Department of Surgery at Yale School of Medicine. In her new role, Dr. Greenup will provide breast surgical oncology leadership across the Smilow Cancer...
Expert Point of View: Roy S. Herbst, MD, PhD, FACP, FASCO, and Shinichi Toyooka, MD
The ASCO Post reached out to Roy S. Herbst, MD, PhD, FACP, FASCO, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, New Haven, for his thoughts on the LCMC3 trial of neoadjuvant atezolizumab.1 Dr. Herbst led...
Caroline Dive, CBE, PhD, FBPhS, FMedSci, Honored With Mary J. Matthews Pathology/Translational Research Award
Caroline Dive, CBE, PhD, FBPhS, FMedSci, Director of the CRUK Manchester Institute Cancer Biomarker Centre, University of Manchester, has been recognized by the International Association for the Study of Lung Cancer (IASLC) with the Mary J. Matthews Pathology/Translational Research Award. The award ...
Study Finds More Than Half of Cancer Survivors Have Underlying Medical Conditions Associated With Developing Severe COVID-19
A new study found that more than half (56.4%) of cancer survivors in the United States reported having additional underlying medical conditions associated with severe COVID-19 illness.1 The report, appearing in JNCI: The Journal of the National Cancer Institute, suggests that the prevalence of...
Expert Point of View: Rina Hui, MBBS, PhD, and Melina Marmarelis, MD
“It has been a long time coming to see a positive randomized phase III study with a checkpoint inhibitor in relapsed mesothelioma,” said the study’s invited discussant, Rina Hui, MBBS, PhD, Clinical Professor of Medicine, Crown Princess Mary Cancer Centre, Westmead Hospital, University of Sydney,...
Moise Danielpour, MD, Named Editor-in-Chief of Pediatric Neurosurgery
Pediatric neurosurgeon Moise Danielpour, MD, Director of the Cedars-Sinai Pediatric Neurosurgery Program, was recently appointed Editor-in-Chief of the journal Pediatric Neurosurgery. “I am delighted and honored to take over the helm of the journal, following in the footsteps of previous editors...
Expert Point of View: Frank Keller, MD, and E. Anders Kolb, MD
Frank Keller, MD, a pediatric hematologist/oncologist with Children’s Healthcare of Atlanta–Egleston Hospital, and E. Anders Kolb, MD, Director of the Nemours Center for Cancer and Blood Disorders, Nemours Children’s Health System in Delaware, provided comments on the studies for The ASCO Post....
Overcoming Gender Disparity in Evaluating Sexual Health Following a Cancer Diagnosis
The results from a recent study showcase the disturbing prevalence of sexual dysfunction as a treatment side effect of cancer and gender disparity in how the problem is addressed by physicians.1 The study, conducted by James Taylor, MD, MPH, Chief Resident in the Department of Radiation Oncology at ...
Fred R. Hirsch, MD, PhD, on Searching for Therapeutic Strategies for Patients With Lung Cancer and COVID-19 Infection
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, invites his colleagues to enroll their patients in a large prospective study, for which he serves as Principal Investigator. The study is searching for solutions for treating patients with lung cancer who also have the coronavirus, because so...
The Emerging Role of Exercise in Cancer Prevention and Treatment
The holistic benefits derived from exercise in preventing and ameliorating chronic health conditions such as cardiovascular disease and diabetes are well documented. However, less is known about the salutary effects exercise may have across the cancer setting, especially during treatment....
USPSTF Issues Final Recommendation Statement on Screening for Lung Cancer
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for lung cancer in people who do not have signs or symptoms. Based on the evidence, the USPSTF recommends yearly screening using a low-dose computed tomography (CT) scan for people aged...
New Global Breast Cancer Initiative Highlights Renewed Commitment to Improve Survival
A major new collaborative effort, the Global Breast Cancer Initiative, was introduced by the World Health Organization (WHO), with the objective of reducing global breast cancer mortality by 2.5% per year until 2040, thereby averting an estimated 2.5 million deaths. In recognition of International ...
Memorial Sloan Kettering Announces Newly Endowed Chair and Fellowships for Health Equity and Diversity
Memorial Sloan Kettering Cancer Center (MSK) has announced the newly established Nicholls-Biondi Chair for Health Equity. This permanently endowed chair is dedicated to improving outcomes for patients from medically underserved communities and building a base of knowledge to facilitate health...
Hossein Borghaei, DO, on Bispecific T-Cell–Engager Immune Therapy for Small Cell Lung Cancer
Hossein Borghaei, DO, of Fox Chase Cancer Center, discusses phase I results from a study of AMG 757, an experimental bispecific T-cell–engager (BiTE) immune therapy aimed at the DLL3 molecular target in patients with small cell lung cancer. At this early stage, results show clinical efficacy and...
Atezolizumab’s Indication in Previously Treated Metastatic Bladder Cancer Is Withdrawn
Genentech, a member of the Roche Group, announced on March 8 that the company is voluntarily withdrawing the U.S. indication for atezolizumab (Tecentriq) in patients with prior platinum-treated metastatic urothelial carcinoma. This decision was made in consultation with the U.S. Food and Drug...
FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma
On March 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to axicabtagene ciloleucel (Yescarta) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. ZUMA-5 Approval in follicular lymphoma was based on a...
David Fajgenbaum, MD, MBA, on Repurposing Cancer Drugs to Treat COVID-19
David Fajgenbaum, MD, MBA, of the University of Pennsylvania, talks about his research efforts to find an already-approved drug that could treat his orphan disease—multicentric Castleman disease—and how that methodology may be applied to the coronavirus and the cytokine storm it can cause...
New WHO/IAEA Publication Provides Guidance on Radiotherapy Equipment Procurement
New guidance from the World Health Organization (WHO) and the International Atomic Energy Agency (IAEA) on the procurement of radiotherapy equipment could improve access to this life-saving cancer treatment option across the world. The new technical guidance aims to ensure that the selection of...
Childhood Cancer Survivors and Health-Care Providers Satisfied With Video Visits During the COVID-19 Pandemic
When the COVID-19 pandemic limited in-person medical checkups last year, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center offered video visits for the first time for long-term follow-up appointments for childhood cancer survivors. Due to the pandemic, virtual visits were adopted...
Giuseppe Curigliano, MD, PhD: In the Face of COVID, Continuity in Cancer Care
Giuseppe Curigliano, MD, PhD, of the University of Milan and Istituto Europeo Oncologico, talks about designing public health measures focused on COVID-19 morbidity and mortality for cancer patients, defining treatment and vaccine priorities, and creating a model to assess the impact of control...
